Ascentage Pharma Group International American Depository Shares AAPG

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.

• GlobeNewswire Inc. 2 ago

  Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer

  Ascentage Pharma announced the appointment of Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer to strengthen global business development and US commercialization efforts. Both executives bring extensive experience in oncology and specialty therapeutics, with the company advancing multiple Phase III registrational studies for its pipeline of cancer therapies.

  

• GlobeNewswire Inc. 26 jul

  Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026

  Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, has been recognized in The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category. The recognition highlights the company's achievements in advancing innovative cancer therapies, including the commercialization of olverembatinib and lisaftoclax, with multiple global Phase III clinical trials underway.

  

• GlobeNewswire Inc. 14 jun

  Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

  Ascentage Pharma announced seventeen clinical updates from its core assets at the 31st European Hematology Association Congress, including eight poster presentations. Key data showed olverembatinib demonstrated deep and durable responses in chronic myeloid leukemia (CML) patients resistant to first-line therapy and robust clinical response in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Lisaftoclax showed promising efficacy in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and myeloid neoplasms, with a chemotherapy-free combination regimen yielding encouraging results in pediatric patients with relapsed/refractory Ph+ ALL.